Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Alexza Pharma Jumps on Adasuve Licensing Deal

By Pharmaceutical Processing | May 9, 2013

NEW YORK (AP) — Shares of Alexza Pharmaceuticals Inc. jumped Wednesday after the company said Teva Pharmaceutical Industries Ltd., one of the world’s largest drug companies, will market is agitation drug Adasuve in the U.S.

THE SPARK: The companies said Wednesday that Teva will be responsible for all U.S. commercial and clinical-related activities, including a required post-approval study. Teva will also have the right to study the drug as a treatment for other neurological disorders. Alexza, of Mountain View, Calif., will manufacture the drug and supply it to Teva.

The Israeli company will pay Alexza $40 million upfront and it could make another $195 million in milestone payments based on completion of post-approval studies and sales targets. Alexza will also receive royalties on sales of the drug, and Teva will lend Alexza up to $25 million to support Adasuve activities over the next five years.

THE BIG PICTURE: Adasuve is Alexza’s first approved product. The drug is an inhaled treatment for agitation in patients with schizophrenia or bipolar disorder. The Food and Drug Administration cleared it in December and European Union regulators approved it in February.

Teva is the world’s largest maker of generic drugs, and it also sells brand-name drugs like the multiple sclerosis treatment Copaxone. It reported $20.32 billion in revenue in 2012.

Groupo Ferrer International holds the marketing rights to Adasuve in Europe, Latin America, Russia and the Commonwealth of Independent States.

THE ANALYSIS: Roth Capital Partners analyst Scott Henry said the agreement is a “major positive” for Alexza and said he believes the royalty payments will be around 20 percent of total sales revenue. Henry wrote that Teva is now assuming the risks related to launching Adasuve, and its decision to do so will be interpreted as a vote of confidence in the drug.

He maintained a “Buy” rating on Alexza shares.

SHARE ACTION: Shares of Alexza gained $1.12, or 25.8 percent, to $5.47 in afternoon trading. Earlier the shares rose to an annual high of $6.65.

Shares of Teva picked up 27 cents to $38.62.

 

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE